A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma

Case Rep Oncol. 2017 Jun 9;10(2):493-500. doi: 10.1159/000477337. eCollection 2017 May-Aug.

Abstract

We present a muscle-invasive high-grade metastatic urothelial carcinoma patient, aged 71 years, with rapid progression from the diagnosis and a poor prognosis after 3 lines of treatment. A clinical exhaustive genomic profile was performed with the goal of finding potential actionable molecular alterations. The patient showed significant symptomatic and laboratory improvement with a nonstandard chemotherapy combination treatment identified by the molecular profiling, which would otherwise not have been considered. This approach illustrates the clinical benefit of a comprehensive genomic analysis in an aggressive and refractory urothelial carcinoma.

Keywords: Abraxane; Adriamycin; Immunohistochemistry; Next-generation sequencing; RB1; TOP2A; TUBB3; Urothelial carcinoma.

Publication types

  • Case Reports